menu
    • menu
    [{"orgOrder":0,"company":"Cerevance","sponsor":"Google Ventures","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Series B Financing","leadProduct":"CVN424","moa":"D2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Cerevance","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Cerevance \/ Google Ventures","highestDevelopmentStatusID":"8","companyTruncated":"Cerevance \/ Google Ventures"},{"orgOrder":0,"company":"Cerevance","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"CVN424","moa":"D2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Cerevance","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Cerevance \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cerevance \/ Not Applicable"},{"orgOrder":0,"company":"Cerevance","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"C101248","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Cerevance","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Cerevance \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Cerevance \/ Not Applicable"},{"orgOrder":0,"company":"Cerevance","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"C101248","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Cerevance","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Cerevance \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Cerevance \/ Not Applicable"},{"orgOrder":0,"company":"Cerevance","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"CVN766","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Cerevance","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Cerevance \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cerevance \/ Not Applicable"},{"orgOrder":0,"company":"Cerevance","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Cerevance","amount2":1.1299999999999999,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":1.1299999999999999,"dosageForm":"","sponsorNew":"Cerevance \/ Merck & Co. Inc.","highestDevelopmentStatusID":"3","companyTruncated":"Cerevance \/ Merck & Co. Inc."},{"orgOrder":0,"company":"Cerevance","sponsor":"Gates Frontier","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Series B Financing","leadProduct":"CVN424","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"Cerevance","amount2":0.12,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0.12,"dosageForm":"","sponsorNew":"Cerevance \/ Gates Frontier","highestDevelopmentStatusID":"8","companyTruncated":"Cerevance \/ Gates Frontier"},{"orgOrder":0,"company":"Cerevance","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"CVN293","moa":"","graph1":"Neurology","graph2":"Phase I","graph3":"Cerevance","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Cerevance \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cerevance \/ Not Applicable"},{"orgOrder":0,"company":"Cerevance","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"CVN424","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"Cerevance","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cerevance \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cerevance \/ Not Applicable"},{"orgOrder":0,"company":"Cerevance","sponsor":"Agent Capital","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Series B Financing","leadProduct":"CVN424","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"Cerevance","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0.10000000000000001,"dosageForm":"Tablet","sponsorNew":"Cerevance \/ Agent Capital","highestDevelopmentStatusID":"8","companyTruncated":"Cerevance \/ Agent Capital"},{"orgOrder":0,"company":"Cerevance","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Cerevance","amount2":1.1299999999999999,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":1.1299999999999999,"dosageForm":"","sponsorNew":"Cerevance \/ Merck & Co","highestDevelopmentStatusID":"3","companyTruncated":"Cerevance \/ Merck & Co"},{"orgOrder":0,"company":"Cerevance","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Cerevance","amount2":1.1299999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Cerevance \/ Merck & Co","highestDevelopmentStatusID":"12","companyTruncated":"Cerevance \/ Merck & Co"},{"orgOrder":0,"company":"Cerevance","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"CVN293","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Cerevance","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Cerevance \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Cerevance \/ Not Applicable"},{"orgOrder":0,"company":"Cerevance","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Solengepras","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Cerevance","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Cerevance \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Cerevance \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Cerevance

    Menu

    Cerevance

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Cerevance

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Cerevance

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Solengepras

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Cerevance Doses First Patient in Phase 3 ARISE Trial for Parkinson’s Disease

                            Details : CVN424 (solengepras) is a first-in-class non-dopamine therapy that selectively modulates GPR6, being investigated for the treatment option for individuals with early-stage Parkinson’s disease.

                            Brand Name : CVN424

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 18, 2024

                            Lead Product(s) : Solengepras

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Cerevance

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Cerevance

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CVN293

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Cerevance’s CVN293 Demonstrated Positive Phase 1 Results in Healthy Volunteers

                            Details : CVN293 is designed to inhibit KCNK13, a potentially novel target involved in activating the NLRP3 inflammasome. It is being evaluated for the treatment of frontotemporal dementia.

                            Brand Name : CVN293

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 11, 2024

                            Lead Product(s) : CVN293

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Cerevance

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Cerevance

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Merck & Co

                            Deal Size : $1,125.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Cerevance Achieves Second Milestone in Research Collaboration with Merck

                            Details : The collaboration focuses on the identification and validation of novel therapeutic targets for Alzheimer’s disease using NETSseq platform.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : $25.0 million

                            October 08, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Merck & Co

                            Deal Size : $1,125.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Cerevance

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Cerevance

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Study Phase : Discovery

                            Sponsor : Merck & Co

                            Deal Size : $1,125.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Cerevance Achieves First Milestone in Research Collaboration with Merck

                            Details : Through the research collaboration, Cerevance is concentrating on identifying novel therapeutic candidates for the treatment of patients with alzheimer's disease.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : $25.0 million

                            May 02, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Highest Development Status : Discovery

                            Sponsor : Merck & Co

                            Deal Size : $1,125.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Cerevance

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Cerevance

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CVN424

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Agent Capital

                            Deal Size : $98.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Cerevance Adds $47 Million in Series B-1 Extension to Advance Robust Clinical Pipeline

                            Details : The financing is intended to support the clinical development of CVN424, which is being investigated as a treatment option for individuals with early-stage Parkinson’s disease.

                            Brand Name : CVN424

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            April 25, 2024

                            Lead Product(s) : CVN424

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Agent Capital

                            Deal Size : $98.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Cerevance

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Cerevance

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CVN424

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Cerevance Doses First Patient in ASCEND Phase 2 Clinical Study of CVN424, a First-in-Class, Non-Dopaminergic T...

                            Details : CVN424 is a first-in-class non-dopamine therapy that selectively modulates GPR6, an orphan G-protein coupled receptor, which is investigated for the treatment option for individuals with early-stage Parkinson’s disease.

                            Brand Name : CVN424

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 13, 2023

                            Lead Product(s) : CVN424

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Cerevance

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Cerevance

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CVN293

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Cerevance Doses First Subject in Phase 1 Clinical Study of CVN293, a Selective Inhibitor of KCNK13 Designed to...

                            Details : CVN293 is an investigational, potent, and selective inhibitor of KCNK13 and has been implicated in many neurodegenerative diseases, including Amyotrophic Lateral Sclerosis, Alzheimer’s disease and severe age-related macular degeneration.

                            Brand Name : CVN293

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 19, 2023

                            Lead Product(s) : CVN293

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Cerevance

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Cerevance

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CVN424

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Gates Frontier

                            Deal Size : $116.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Cerevance Expands Series B Financing with Additional $51 Million

                            Details : The financing will support upcoming clinical trials focused on Parkinson’s disease, Amyotrophic Lateral Sclerosis, and schizophrenia including CVN424, a first-in-class, oral, brain penetrant, non-dopaminergic, GPR6 inverse agonist in Phase 2 trial for ...

                            Brand Name : CVN424

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            February 13, 2023

                            Lead Product(s) : CVN424

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Gates Frontier

                            Deal Size : $116.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Cerevance

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Cerevance

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CVN766

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Cerevance Announces Positive Topline Data from Phase 1 Clinical Trial of CVN766 for the Potential Use in the T...

                            Details : CVN766 is a potent antagonist of the Ox1R with high selectivity over Ox2R (>1000 fold). Ox1R has genetic links to domains of psychiatric disorders and is expressed in areas of the brain important for regulating emotion, fear, anxiety and motivation.

                            Brand Name : CVN766

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            January 09, 2023

                            Lead Product(s) : CVN766

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Cerevance

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Cerevance

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : C101248

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Cerevance Announces Presentation of Preclinical Data During the Cold Spring Harbor Laboratory (CSHL) Neurodege...

                            Details : CN101248, the first selective small molecule THIK-1 inhibitor, attacks neuroinflammation via THIK-1 and have observed beneficial effects on neuroinflammation with this compound.

                            Brand Name : C101248

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 30, 2022

                            Lead Product(s) : C101248

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth